Get the Stockscreener App
3.16
1.94%
0.06
Pre-market:
3.13
-0.03
-0.95%
Anixa Biosciences Inc stock is traded at $3.16, with a volume of 87,717.
It is up +1.94% in the last 24 hours and down -1.86% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$3.10
Open:
$3.26
24h Volume:
87,717
Relative Volume:
0.69
Market Cap:
$101.79M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-8.1026
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
-6.51%
1M Performance:
-1.86%
6M Performance:
+7.48%
1Y Performance:
+2.27%
1-Day Range:
$3.12
$3.2786
1-Week Range:
$3.10
$3.41
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.16 | 99.85M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences stock rises after securing Canadian patent allowance - Investing.com Australia
Anixa Biosciences receives Canadian patent allowance for breast cancer vaccine - Investing.com Australia
First-Ever Breast Cancer Prevention Vaccine Technology Expands Global Patent Protection in Canada - Stock Titan
How Anixa Biosciences Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it
Anixa Biosciences Inc. Earnings Report Breakdown: What Investors Should KnowEntry Plan for Oversold Reversal Stocks Released - metal.it
Should I hold or sell Anixa Biosciences Inc. stock in 2025Powerful market insights - jammulinksnews.com
What are the technical indicators suggesting about Anixa Biosciences Inc.Earnings Report Alerts For Every Investor - jammulinksnews.com
How does Anixa Biosciences Inc. compare to its industry peersMaximize your returns with expert insights - jammulinksnews.com
How many analysts rate Anixa Biosciences Inc. as a “Buy”Build wealth steadily with expert advice - jammulinksnews.com
What are analysts’ price targets for Anixa Biosciences Inc. in the next 12 monthsExplosive wealth accumulation - jammulinksnews.com
How strong is Anixa Biosciences Inc. company’s balance sheetBuild wealth with reliable stock picks - jammulinksnews.com
How Efficient Is Anixa Biosciences Inc. at Controlling Operating CostsFree Stock Movement Tracking - metal.it
What are the latest earnings results for Anixa Biosciences Inc.Achieve fast wealth growth with smart picks - jammulinksnews.com
Why is Anixa Biosciences Inc. stock attracting strong analyst attentionGrow your portfolio with growth-oriented stocks - jammulinksnews.com
What is the dividend policy of Anixa Biosciences Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
How volatile is Anixa Biosciences Inc. stock compared to the marketConsistent wealth multiplication - jammulinksnews.com
When is Anixa Biosciences Inc. stock expected to show significant growthFree Expert Stock Watchlist - jammulinksnews.com
Is Anixa Biosciences Inc. stock overvalued or undervaluedTremendous return rates - jammulinksnews.com
Why Anixa Biosciences Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - metal.it
What analysts say about Anixa Biosciences Inc. stockExplosive capital gains - PrintWeekIndia
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Anixa Biosciences Inc. a good long term investmentSuperior risk-adjusted returns - PrintWeekIndia
What institutions are buying Anixa Biosciences Inc. stock nowBreakthrough profits - jammulinksnews.com
Anixa Biosciences receives new patent for breast cancer vaccine technology - Investing.com Australia
Revolutionary Breast Cancer Prevention Vaccine Secures Patent Protection Until 2040s$Billion Market Potential - Stock Titan
What drives Anixa Biosciences Inc. stock priceBreakthrough capital growth - Autocar Professional
Anixa Biosciences director Baskies buys $16,950 in stock By Investing.com - Investing.com South Africa
Anixa Biosciences director Baskies buys $16,950 in stock - Investing.com
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
| KUMAR AMIT | Chief Executive Officer |
Jan 15 '25 |
Buy |
2.23 |
43,000 |
95,890 |
559,925 |
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):